Onc Now: Breaking Barriers in Cancer Immunotherapy

Onc Now

In this episode of Onc Now, Andrew Furness explores the evolving field of solid tumour immunotherapy, from tumour-infiltrating lymphocyte therapy in advanced melanoma to cellular therapy infrastructure, patient selection, and future research priorities.

Speaker bio:

Andrew Furness

Andrew Furness is a consultant medical oncologist at the Royal Marsden Hospital, London, UK, treating patients with skin and kidney cancers. He is also Team Leader and Clinical Lead of the Centre for Translational Immunotherapy at the Institute of Cancer Research, London, UK.

Timestamps:

00:00 – Introduction
01:10 – Journey into medical oncology
07:11 – Translational immunotherapy research
11:50 – Tumour-infiltrating lymphocyte therapy
21:30 – Cellular therapy infrastructure barriers
26:35 – Improving immunotherapy patient selection
31:21 – ESMO and emerging areas
32:45 – Three wishes for immunotherapy

Disclaimer: The opinions expressed in this episode belong to the speakers and do not necessarily represent the opinions of EMJ.

Onc Now: Breaking Barriers in Cancer Immunotherapy

Onc Now

Nomograms Predict Survival in Rare Prostate Cancer

Infection-Related Cancers Cause One in Eight Cases Globally

More articles

The Next Era of Breast Cancer Care: Penny Kechagioglou

Recent Developments in NMIBC Research

The Next Generation of Melanoma Treatment: Interview with Meredith McKean

Featured journals

AMJ Oncology 3.1 2026

AMJ Oncology 3 [Supplement 4] 2026

Therapy Area

About Us

Onc Now: Breaking Barriers in Cancer Immunotherapy

Onc Now

Related To This Subject

Nomograms Predict Survival in Rare Prostate Cancer

Infection-Related Cancers Cause One in Eight Cases Globally

More articles

The Next Era of Breast Cancer Care: Penny Kechagioglou

Recent Developments in NMIBC Research

The Next Generation of Melanoma Treatment: Interview with Meredith McKean

Featured journals

AMJ Oncology 3.1 2026

AMJ Oncology 3 [Supplement 4] 2026